scholarly journals Recurrent hepatocellular carcinoma: comparison between repeat hepatectomy and local ablation

HPB ◽  
2016 ◽  
Vol 18 ◽  
pp. e865
Author(s):  
L. Lacaze ◽  
O. Goria ◽  
J.P. Lestrat ◽  
M. Bubenheim ◽  
M. Scotte
Keyword(s):  
Hepatocellular Carcinoma ◽  
Repeat Hepatectomy ◽  
Local Ablation ◽  
Recurrent Hepatocellular Carcinoma

scholarly journals Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Fuqun Wei ◽  
Qizhen Huang ◽  
Yang Zhou ◽  
Liuping Luo ◽  
Yongyi Zeng
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Repeat Hepatectomy ◽  
Free Survival ◽  
Recurrent Hepatocellular Carcinoma ◽  
Primary Endpoints ◽  
Grade 3 ◽  
Optimal Treatment Strategy ◽  
Hepatectomy Group

Abstract Background Repeat hepatectomy and radiofrequency ablation (RFA) are widely used to treat early recurrent hepatocellular carcinoma (RHCC) located in the subcapsular region, but the optimal treatment strategy remains to be controversial. Methods A total of 126 RHCC patients in the subcapsular location after initial radical hepatectomy were included in this study between Dec 2014 and Jan 2018. These patients were divided into the RFA group (46 cases) and the repeat hepatectomy group (80 cases). The primary endpoints include repeat recurrence-free survival (rRFS) and overall survival (OS), and the secondary endpoint was complications. The propensity-score matching (PSM) was conducted to minimize the bias. Complications were evaluated using the Clavien-Dindo classification, and severe complications were defined as classification of complications of ≥grade 3. Results There were no significant differences in the incidence of severe complications were observed between RFA group and repeat hepatectomy group in rRFS and OS both before (1-, 2-, and 3-year rRFS rates were 65.2%, 47.5%, and 33.3% vs 72.5%, 51.2%, and 39.2%, respectively, P = 0.48; 1-, 2-, and 3-year OS rates were 93.5%, 80.2%, and 67.9% vs 93.7%, 75.8%, and 64.2%, respectively, P = 0.92) and after PSM (1-, 2-, and 3-year rRFS rates were 68.6%, 51.0%, and 34.0% vs 71.4%, 42.9%, and 32.3%, respectively, P = 0.78; 1-, 2-, and 3-year OS rates were 94.3%, 82.9%, and 71.4% vs 88.6%, 73.8%, and 59.0%, respectively, P = 0.36). Moreover, no significant differences in the incidence of severe complications were observed between the RFA group and repeat hepatectomy group. Conclusion Both repeat hepatectomy and RFA are shown to be effective and safe for the treatment of RHCC located in the subcapsular region.

scholarly journals Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma After Curative Resection: A 10-Year Single-Center Comparative Study

2021 ◽  
Vol 11 ◽  
Author(s):  
Xin Zheng ◽  
Yanqiao Ren ◽  
Hanqing Hu ◽  
Kun Qian
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiofrequency Ablation ◽  
Transarterial Chemoembolization ◽  
Curative Resection ◽  
Progression Free Survival ◽  
Repeat Hepatectomy ◽  
Tumor Diameter ◽  
Recurrent Hepatocellular Carcinoma ◽  
Significant Difference ◽  
Hepatectomy Group

BackgroundThe purpose of this study was to compare the efficacy and safety of transarterial chemoembolization (TACE) in combination with radiofrequency ablation (RFA) (TACE-RFA) and repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma (HCC) after curative resection.MethodsThis retrospective study evaluated consecutive medical records of patients who received either TACE-RFA or repeat hepatectomy between January 2010 and May 2021. Overall survival (OS), progression-free survival (PFS), and complications were compared.ResultsOf the 2672 patients who received either TACE-RFA or repeat hepatectomy, 111 eligible patients were included in our study, 63 in the TACE-RFA group and 48 in the repeat hepatectomy group. The median OS was 38 months in the TACE-RFA group and 42 months in the repeat hepatectomy group, with no statistically difference between the two groups (P=0.45). Meanwhile, there was also no statistically significant difference in PFS between the two groups (P=0.634). Although both groups achieved similar outcomes, the rate of major complications was significantly higher in the repeat hepatectomy group (P=0.003).ConclusionsPatients with recurrent HCC in the TACE-RFA group and the repeat hepatectomy group had similar OS and PFS regardless of the patient’s tumor diameter, but the TACE-RFA group was safer and more minimally invasive.

Repeat hepatectomy for recurrent hepatocellular carcinoma

Surgery ◽  
2007 ◽  
Vol 141 (5) ◽  
pp. 589-597 ◽  
Author(s):  
Toshiyuki Itamoto ◽  
Hideki Nakahara ◽  
Hironobu Amano ◽  
Toshihiko Kohashi ◽  
Hideki Ohdan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Repeat Hepatectomy ◽  
Recurrent Hepatocellular Carcinoma

scholarly journals Selection Criteria for Repeat Hepatectomy in Patients With Recurrent Hepatocellular Carcinoma

2003 ◽  
Vol 238 (5) ◽  
pp. 703-710 ◽  
Author(s):  
Masami Minagawa ◽  
Masatoshi Makuuchi ◽  
Tadatoshi Takayama ◽  
Norihiro Kokudo
Keyword(s):  
Hepatocellular Carcinoma ◽  
Selection Criteria ◽  
Repeat Hepatectomy ◽  
Recurrent Hepatocellular Carcinoma

Salvage liver transplantation or repeat hepatectomy for recurrent hepatocellular carcinoma: An intent-to-treat analysis

2017 ◽  
Vol 23 (12) ◽  
pp. 1553-1563 ◽  
Author(s):  
Chetana Lim ◽  
Hiroji Shinkawa ◽  
Kiyoshi Hasegawa ◽  
Prashant Bhangui ◽  
Chady Salloum ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Repeat Hepatectomy ◽  
Recurrent Hepatocellular Carcinoma ◽  
Salvage Liver Transplantation ◽  
Intent To Treat ◽  
Treat Analysis
Sign in / Sign up

Export Citation Format

Share Document